Renewed Political Pressure on Hydroxychloroquine for COVID Highlights Need For Independent US FDA
Executive Summary
Bowing to President Trump’s latest push to authorize the anti-malarial drug for COVID-19 could damage the reputation of the agency for the duration of the pandemic and beyond, experts say, arguing it may be the best example yet of why the FDA’s decision making needs to be more clearly delineated from the country’s political leadership.
You may also be interested in...
US FDA Denies Petition Seeking Freeze On Russian Companies’ Regulatory Activities
Agency tells former OOPD director Tim Coté it doesn't have the authority to consider sponsor’s country of origin when determining whether to act on applications. Despite the denial of petition, FDA continues to support Ukraine.
US FDA Denies Petition Seeking Freeze On Russian Companies’ Regulatory Activities
The agency tells former OOPD Director Tim Coté that it does not have the authority to consider the sponsor’s country of origin when determining whether to act on an application.
Former Official Petitions US FDA To Stop Reviewing Russian Firms' Applications Amid Ukraine Invasion
Request from Tim Coté, former Office of Orphan Products Development director, could drag agency back into a political arena it's been trying to avoid. Coté, now consulting through Only Orphans Coté, filed a citizen petition asking agency to “completely freeze all administrative actions on any regulatory requests,” from drug and device companies headquartered in Russia or with majority Russian ownership.